Jonathan Avery, MD, director of addiction psychiatry, New York-Presbyterian Hospital, Weill Cornell Medical Center, explained why it’s important to diagnose and treat concurrent substance use disorders and mental illnesses at the same time.
Jonathan Avery, MD, director of addiction psychiatry, New York-Presbyterian Hospital, Weill Cornell Medical Center, explained why it’s important to diagnose and treat concurrent substance use disorders and mental illnesses at the same time.
Transcript
What can happen if a psychological disorder is treated but substance use is left undiagnosed or vice versa?
The big problem, I think, in American psychiatry or in medicine in general is that we tend to only treat 1 condition at a time, and often it’s the psychiatric condition and not the substance use disorder condition that gets treated. We think in an ideal world both should be treated at the same time, and if not, if you just treat the psychiatric condition and not the substance use, things aren’t going to get better, and similarly if you address the substance use without addressing the reason why they’re using, it sets the person up for failure. So you really have to address both at the same time if you want the person to get on the right track.
What are the dangers of misdiagnosing a psychiatric disorder when a substance use disorder is present?
Diagnosis can be very challenging when people are using substances. It’s unclear, as we were discussing, if the substance use leads to the mental illness, if the mental illness symptoms wouldn’t be there if they weren’t using a substance. These days, though, we sort of argue that things should be just kept simple, that if it looks like they have depressive symptoms, we don’t have to completely figure out if the substance use was related but they should all be addressed. So if it’s, say, someone who’s depressed and drinking a lot, it might be hard to tease out what started first—if the depression started first or the drinking started first—and our goal would be to recommend that you treat both. You give them medications for the substance, for the alcohol use, or the psychosocial treatment, and you give them meds and therapy if needed for the depression.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More